Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cero Therapeutics Holdings Q3 2026 Results: Turns Profitable, Net Income $4.02M

CERo Therapeutics Holdings, Inc. is an emerging growth company focused on developing its lead product candidate, CER-1236. As of November 13, 2026, the company reported 83,309,742 shares of common stock outstanding and noted the impact of its delisting from Nasdaq as a significant risk factor.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income4.0-4.9
EPS (diluted, $ a share)$0.00$-9.10

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: CERO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cero Therapeutics Holdings, Inc.: key numbers

Share price
$0.0041Close, Nov 17
Market cap
$337K
Shares outstanding
83.31MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cero Therapeutics Holdings, Inc.

All →
8:30 AM ET 8-K
Divestiture

Cero Therapeutics Holdings Divestiture to SRX Global Inc. for $10.8M

CERo Therapeutics Holdings, Inc. entered into a definitive agreement to sell its wholly owned operating subsidiary, CERo Therapeutics, Inc., to SRX Global Inc. The consideration includes $1 million in SRX common stock, the assumption of approximately $1.562 million in liabilities, and the forgiveness of a senior secured promissory note with an outstanding balance of approximately $8.25 million. The agreement includes a 30-day 'go-shop' period allowing the company to solicit superior proposals.

Value
$10.8M
Counterparty
SRX Global Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.